Ciprofol vs Propofol for Reducing Hypoxia Incidence in ERCP

NCT06015074 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2024-05-31

No results posted yet for this study

Summary

Intravenous anesthesia has been widely used in endoscopic retrograde cholangiopancreatography (ERCP). In the past decade, many practices have been carried out under the propofol-based monitored anesthesia care without endotracheal intubation in patients undergoing ERCP.

Ciprofol is a newly developed intravenous anesthetic with a potency 4-5 times than that of propofol. Ciprofol seems a promising anesthetic agent for intravenous anesthesia but the evidence supported its application in ERCP is still limited.

Conditions

  • Anesthesia; Adverse Effect
  • Biliary Tract Diseases

Interventions

DRUG

Propofol

patients in Propofol group receive sufentanil(0.1ug/kg)+ propofol (1.5-2mg/kg) for anesthesia induction, and continuous infusion of propofol 5mg/kg/h for anesthesia maintain.

DRUG

Ciprofol

patients in Ciprofol group receive sufentanil(0.1ug/kg)+ ciprofol(0.4-0.5mg/kg) for anesthesia induction, and continuous infusion of ciprofol 0.8mg/kg/h for anesthesia maintain.

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Peiying Li, Doctor · Clinial Research Center, Renji Hospital

  • Yu Weifeng, Doctor · Department of Anesthesiology, Renji Hospital

  • Zheng Li, Master · Department of Anesthesiology, Renji Hospital

  • Yanhua Zhao, Doctor · Department of Anesthesiology, Renji Hospital

  • Yifeng Qu, Master · Department of Anesthesiology, Renji Hospital

  • Kun Luo, Master · Department of Anesthesiology, Renji Hospital

  • Guangyan Wang · Operating Room,Renji Hospital

  • Teng Wang · Department of Anesthesiology, Renji Hospital

  • Huichen Zhu, Master · Department of Anesthesiology, Renji Hospital

  • Jing Gao, Doctor · Clinial Research Center, Renji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-15
Primary Completion
2024-12-31
Completion
2025-02-28

Countries

  • China

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06015074 on ClinicalTrials.gov